Expression of concern

Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysis

Paper Information

Record ID:

35137

Author(s):

Kristian Thorlund
Eric Druyts
Edward J Mills
Richard N Fedorak
John K Marshall

Journal:

Journal of Crohn's and Colitis ( Oxford Academic )

Publication Date:

July 01, 2014

Retraction Date:

January 24, 2022 (3.8 years years ago)

Subjects:

Broad Categories:
Medicine

Specific Fields:
Medicine - Gastroenterology Medicine - Pharmacology

Institutions:

Countries:

🇨🇦 Canada 🇺🇸 United States

Article Type:

Meta-Analysis

Publisher:

Oxford Academic

Open Access:

Yes

DOI:

10.1016/j.crohns.2014.01.010

PubMed ID:

24491514

Retraction PubMed ID:

35073579

Expression of concern Details

Retraction Reasons:

Nature of Retraction:

Expression of concern

Retraction Notice:

10.1093/ecco-jcc/jjab227

Additional Notes:

See also: https://doi.org/10.1093/ecco-jcc/jjab225 Journal was previously published by Elsevier until 2015.

Citations (77)

77

Total Citations

10

Post-Retraction
(13.0%)

66

Pre-Retraction

1

Same Day

Post-Retraction Citation Analysis

0 Within 30 days

3 Within 1 year

3 After 2+ years

1123 Days since retraction (latest)

Comparative efficacy and survival of biologics in inflammatory bowel disease in different lines of therapy: the clinician’s view of the problem

A. V. Levitskaya, E. А. Belousova, E. Yu. Lomakina et al. (4 authors)

Koloproktologia

Published: Feb 2025

1123 days after retraction

Navigating the pharmacotherapeutic management of comorbid inflammatory bowel disease and primary sclerosing cholangitis

Brigid C. Pinnuck, Kate D. Lynch

Expert Opinion on Pharmacotherapy

Published: Sep 2024
1 citation

974 days after retraction

Efficacy and Safety of Infliximab Versus Adalimumab in Adult Subjects With Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-Analysis

Ahmed Salman, Mohamed Abdalla Salman, Ahmed Elewa et al. (4 authors)

Cureus Open Access

Published: Jun 2024
1 citation

860 days after retraction

Serum TGF-β1 and CD14 Predicts Response to Anti-TNF-α Therapy in IBD

Štěpán Coufal, Miloslav Kverka, Jakub Kreisinger et al. (20 authors)

Journal of Immunology Research Open Access

Published: Jun 2023
2 citations

512 days after retraction

Anti-TNF Biologicals Enhance the Anti-Inflammatory Properties of IgG N-Glycome in Crohn’s Disease

Maja Hanić, Frano Vučković, Helena Deriš et al. (10 authors)

Biomolecules Open Access

Published: Jun 2023
9 citations

499 days after retraction

Comparative onset of effect of biologics and small molecules in moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis

Mohamed Attauabi, E. Dahl, Johan Burisch et al. (6 authors)

EClinicalMedicine Open Access

Published: Feb 2023
21 citations

388 days after retraction

Physicochemical characterization and functionality comparison of Humira®(adalimumab), Remicade®(infliximab) and Simponi Aria® (golimumab)

Jill L. Kinzer, Troy A. Halseth, Jukyung Kang et al. (9 authors)

International Journal of Pharmaceutics Open Access

Published: Jan 2023
3 citations

367 days after retraction

Hydrogel–metal-organic-framework hybrids mediated efficient oral delivery of siRNA for the treatment of ulcerative colitis

Meng Gao, Yang Chen, Chenghu Wu et al. (7 authors)

Journal of Nanobiotechnology Open Access

Published: Sep 2022
46 citations

224 days after retraction

Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars

Zvonimir Petrić, João Gonçalves, Paulo Paixão

Pharmaceutics Open Access

Published: Aug 2022
12 citations

212 days after retraction

Inflammatory bowel disease in children – from the diagnosis to the treatment Recommendations from Croatian Society for Pediatric Gastroenterology, Hepatology and Nutrition of the Croatian Medical Association

Iva Hojsak, Sanja Kolaček, Zrinjka Mišak et al. (12 authors)

Liječnički vjesnik Open Access

Published: Apr 2022

91 days after retraction

Letter to the Editor

Laurent Peyrin‐Biroulet, Britta Siegmund, Silvio Danese et al. (7 authors)

Journal of Crohn s and Colitis Open Access

Published: Jan 2022

Same day as retraction

Anti-TNF-α agents for refractory intestinal Behçet’s disease: case series and meta-analysis

Shukai Zhan, Caiguang Liu, Na Li et al. (10 authors)

Therapeutic Advances in Gastroenterology Open Access

Published: Jan 2022
5 citations

23 days before retraction

Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis

Juan S. Lasa, Pablo A. Olivera, Silvio Danese et al. (4 authors)

The Lancet. Gastroenterology & hepatology

Published: Nov 2021
284 citations

56 days before retraction

Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy

Dagmar Schierová, Radka Roubalová, Martin Kolář et al. (20 authors)

Cells Open Access

Published: Nov 2021
20 citations

69 days before retraction

Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea

Jae Yong Lee, Kyunghwan Oh, Hee Seung Hong et al. (15 authors)

BMC Gastroenterology Open Access

Published: Oct 2021
7 citations

96 days before retraction

A ‘real‐world’ retrospective multi‐centre cohort study comparing infliximab and adalimumab for the maintenance of remission in ulcerative colitis

Victoria Kronsten, Michael Colwill, Shadab Nayeemuddin et al. (13 authors)

GastroHep Open Access

Published: Jun 2021
1 citation

236 days before retraction

Infliximab versus Adalimumab, Which One Is Better for Ulcerative Colitis?

Eun Soo Kim

Gut and Liver Open Access

Published: Mar 2021
4 citations

315 days before retraction

Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice

Yuka Marutani, Tsutomu Mizoshita, Tomoya Sugiyama et al. (13 authors)

Indian Journal of Gastroenterology

Published: Oct 2020
2 citations

454 days before retraction

Comparative efficacy of antitumor necrosis factor agents and tacrolimus in naïve steroid-refractory ulcerative colitis patients

Moto Kitayama, Yuko Akazawa, Daisuke Yoshikawa et al. (15 authors)

Scientific Reports Open Access

Published: Jul 2020
9 citations

546 days before retraction

Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis

Yong Il Lee, Yehyun Park, Soo Jung Park et al. (6 authors)

Gut and Liver Open Access

Published: Jul 2020
19 citations

570 days before retraction

The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies

Máire Conrad, Judith R. Kelsen

Current Gastroenterology Reports Open Access

Published: Jun 2020
45 citations

588 days before retraction

Therapeutic applications of probiotics in ulcerative colitis: An updated review

Parvirti Dhillon, Kuljit Singh

PharmaNutrition

Published: May 2020
32 citations

617 days before retraction

Using Healthcare Databases to Replicate Trial Findings for Supplemental Indications: Adalimumab in Patients with Ulcerative Colitis

Julia Spoendlin, Rishi Desai, Jessica M. Franklin et al. (6 authors)

Clinical Pharmacology & Therapeutics

Published: Apr 2020
2 citations

642 days before retraction

Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis

Charlotte Hedin, Gina Sado, Nelson Ndegwa et al. (36 authors)

Clinical Gastroenterology and Hepatology Open Access

Published: Feb 2020
31 citations

709 days before retraction

Comparison of long-term outcomes of infliximab vs. adalimumab as treatment for ulcerative colitis in biologic-naive patients

이용일

Unknown Journal

Published: Jan 2020

754 days before retraction

Clinical Features and Outcomes of Tuberculosis in Inflammatory Bowel Disease Patients Treated with Anti-tumor Necrosis Factor Therapy

Jihye Kim, Jong Pil Im, Jae‐Joon Yim et al. (10 authors)

Korean Journal of Gastroenterology Open Access

Published: Jan 2020
5 citations

754 days before retraction

Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study

Minkyung Han, Yoon Suk Jung, Jae Hee Cheon et al. (4 authors)

Yonsei Medical Journal Open Access

Published: Dec 2019
11 citations

756 days before retraction

Recent advances in understanding and managing pediatric inflammatory bowel disease

Bhaskar Gurram, Ashish Patel

F1000Research Open Access

Published: Dec 2019
9 citations

773 days before retraction

Synthesis and anti-inflammatory intestinal activity of new glucocorticoid derivatives

Marcella Gabrielle Mendes Machado, Cauê Benito Scarim, Cléverton Roberto de Andrade et al. (5 authors)

Medicinal Chemistry Research

Published: Nov 2019
4 citations

794 days before retraction

Efficacy and safety of biologic agents and tofacitinib in moderate‐to‐severe ulcerative colitis: A systematic overview of meta‐analyses

Katerina Pantavou, Anneza Yiallourou, Daniele Piovani et al. (8 authors)

United European Gastroenterology Journal Open Access

Published: Oct 2019
36 citations

830 days before retraction

Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan

Luis Hernández, Hiroyo Kuwabara, Anshul Shah et al. (8 authors)

PharmacoEconomics Open Access

Published: Sep 2019
13 citations

853 days before retraction

Medical Management of Inflammatory Bowel Disease

Derrick Eichele, Renée Young

Surgical Clinics of North America

Published: Sep 2019
13 citations

856 days before retraction

Complex TNF-α B cell epitope MAP vaccine alleviates murine ulcerative colitis

Yan Sun, Wensheng Pan, Jun Zhang et al. (7 authors)

International Journal of Molecular Medicine Open Access

Published: Jul 2019
1 citation

931 days before retraction

Ulcerative Colitis

Joseph D. Feuerstein, Alan C. Moss, Francis A. Farraye

Mayo Clinic Proceedings

Published: Jul 2019
326 citations

938 days before retraction

Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study

Nagesh Kamat, Saurabh Kedia, Uday C. Ghoshal et al. (10 authors)

Indian Journal of Gastroenterology

Published: Jan 2019
33 citations

1105 days before retraction

Short- and long-term efficacy of adalimumab salvage therapy after failure of calcineurin inhibitors in steroid-refractory ulcerative colitis

Masafumi Nishio, Yoshito Ishii, Yu Hashimoto et al. (11 authors)

Scandinavian Journal of Gastroenterology

Published: Oct 2018
6 citations

1188 days before retraction

Methods to Compare Adverse Events in Twitter to FAERS, Drug Information Databases, and Systematic Reviews: Proof of Concept with Adalimumab

Karen L. Smith, Su Golder, Abeed Sarker et al. (6 authors)

Drug Safety Open Access

Published: Aug 2018
43 citations

1243 days before retraction

Management of Paediatric Ulcerative Colitis, Part 1

Dan Turner, Frank M. Ruemmele, E Orlanski-Meyer et al. (22 authors)

Journal of Pediatric Gastroenterology and Nutrition Open Access

Published: May 2018
385 citations

1334 days before retraction

Ulcerative Colitis in Elderly People: An Emerging Issue

Wei‐Chen Lin, Ming‐Jen Chen, Cheng‐Hsin Chu et al. (6 authors)

International journal of gerontology Open Access

Published: May 2018
6 citations

1364 days before retraction

Current and prospective biologics and small molecules in the treatment of inflammatory bowel diseases

Milan Buc

Vnitřní lékařství Open Access

Published: Mar 2018

1425 days before retraction

Evidence-based clinical practice guidelines for inflammatory bowel disease

Katsuyoshi Matsuoka, Taku Kobayashi, Fumiaki Ueno et al. (27 authors)

Journal of Gastroenterology Open Access

Published: Feb 2018
649 citations

1444 days before retraction

The impact of biologics in surgical outcomes in ulcerative colitis

Marjorie Argollo, Paulo Gustavo Kotze, Antonino Spinelli et al. (5 authors)

Best Practice & Research Clinical Gastroenterology

Published: Feb 2018
21 citations

1453 days before retraction

The Unfinished Symphony: Golimumab Therapy for Anti-Tumour Necrosis Factor Refractory Crohn’s Disease

Tomer Greener, Karen Boland, A. Hillary Steinhart et al. (4 authors)

Journal of Crohn s and Colitis Open Access

Published: Dec 2017
16 citations

1490 days before retraction

Suppression of inflammation and tissue damage by a hookworm recombinant protein in experimental colitis

Ivana Ferreira, Darren Pickering, Sally Troy et al. (6 authors)

Clinical & Translational Immunology Open Access

Published: Oct 2017
42 citations

1576 days before retraction

Safety Considerations with the Use of Corticosteroids and Biologic Therapies in Mild-to-Moderate Ulcerative Colitis

Raymond K. Cross

Inflammatory Bowel Diseases Open Access

Published: Sep 2017
29 citations

1594 days before retraction

Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy

Tsutomu Mizoshita, Takahito Katano, Satoshi Tanida et al. (10 authors)

Medicine Open Access

Published: Aug 2017
15 citations

1637 days before retraction

Paper citing Adalimumab versus infliximab for the treatment of ...

Unknown Authors

Unknown Journal

Published: Jun 2017

1680 days before retraction

Adalimumab in ulcerative colitis – efficacy, safety and optimization in the era of treat-to target

Miles Sparrow

Expert Opinion on Biological Therapy

Published: Mar 2017
16 citations

1771 days before retraction

Prediction and identification of B-cell epitopes for tumor necrosis factor-α

Jun Zhang, Ying Cui, Yinfang Wu et al. (5 authors)

Molecular Medicine Reports Open Access

Published: Mar 2017
6 citations

1790 days before retraction

Anti-TNF Biologic Therapies Other than Infliximab

Calen A. Steiner, Emily P. Whitfield, Jeremy Adler et al. (4 authors)

Springer eBooks

Published: Jan 2017

1849 days before retraction

Quick Stats

Total Citations: 77

Years Since Retraction: 3.8 years

Open Access: Yes

Last Checked: Jul 24, 2025

Actions

More from this journal Similar subjects View Original Paper View Retraction Notice